A vision for inclusive and transparent health data in the beyond. Learning

Background Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from the intrinsically indolent nature of ASPS.

[1]  A. Rosenberg,et al.  Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[2]  F. Du,et al.  Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.

[3]  J. Blay,et al.  Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  I. Judson,et al.  Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118). , 2017 .

[5]  S. Sleijfer,et al.  Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. , 2015, European journal of cancer.

[6]  Krystal M. Straessler,et al.  Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. , 2014, Cancer cell.

[7]  I. Judson,et al.  Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma , 2014, Clinical Cancer Research.

[8]  S. Steinberg,et al.  Cediranib for metastatic alveolar soft part sarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Dewhirst,et al.  Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.

[10]  P. Casali,et al.  Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Schellens,et al.  Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Mayordomo,et al.  Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts) , 2009, Modern Pathology.

[13]  Huasheng Lu,et al.  Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis* , 2002, The Journal of Biological Chemistry.

[14]  M. Ladanyi,et al.  The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. , 2002, The American journal of pathology.

[15]  Alfons Meindl,et al.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.

[16]  J. Blay,et al.  Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. , 2018, The oncologist.

[17]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[18]  M. Brennan,et al.  Alveolar soft‐part sarcoma. A clinico‐pathologic study of half a century , 1989, Cancer.